, Tracking Stock Market Picks
Enter Symbol:
Curis, Inc. (CRIS) [hlAlert]

up 108.33 %

Curis, Inc. (CRIS) rated Buy by Merriman Curhan Ford

Posted on: Wednesday,  Mar 25, 2009  8:25 AM ET by Merriman Curhan Ford

Merriman Curhan Ford rated Buy Curis, Inc. (NASDAQ: CRIS) on 03/25/2009, when the stock price was $1.20. Since
then, Curis, Inc. has gained 108.33% as of 01/22/2016's recent price of $2.50.
If you would have followed this Merriman Curhan Ford's recommendation on CRIS, you would have gained 108.33% of your investment in 2494 days.

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.

We occupy a unique niche among our investment banking peers: we offer our clients both traditional sell-side equity research and primary market research, and we focus on high-potential sectors such as CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. Our institutional and corporate clients get the best of both worlds: expertise from our analysts and access to experts through our Panel Intelligence platform.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/25/2009 8:25 AM Buy
as of 12/31/2009
1 Week down  -19.36 %
1 Month up  6.89 %
3 Months up  19.23 %
1 YTD up  132.50 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy